Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow-Up of a Multicenter, Retrospective Real-World Experience With 321 Cases Outside of Controlled Clinical Trials